ANAB 股价走势图
ANAB 财报
AnaptysBio Inc
$69.28
-0.71%
$-0.5
收盘价：May 05, 16:00:00 GMT-4
$69.29
0.01%
$0.01
盘后：May 05, 20:00:00 GMT-4
返回
AnaptysBio Inc (ANAB) 财报
关键数据
前收盘价
$69.78
开盘价
$70.93
当日区间
$68.3 - $72.27
52周范围
$17.1 - $73.3
交易量
430.7K
平均成交量
566.0K
股息收益率
--
每股收益（TTM）
-0.32
市值
$1.9B
什么是 ANAB？
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 104 full-time employees. The company went IPO on 2017-01-26. The firm manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The firm's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The firm's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
